Praxis Precision Medicines Inc（PRAX）の財務PRAXPraxis Precision Medicines Inc

Evaluating the bottom line, Praxis Precision Medicines, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.86%, provide a clear picture of how effectively PRAX converts its operational activities into shareholder value.

In the context of the broader market, PRAX competes directly with industry leaders such as IONS and ALKS. With a market capitalization of $7.26B, it holds a significant position in the sector. When comparing efficiency, PRAX's gross margin of N/A stands against IONS's 98.98% and ALKS's 75.67%. Such benchmarking helps identify whether Praxis Precision Medicines, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 100% for Q4 2024, but has faced significant net losses, with a net income of -58.68 million USD in Q4 2024 and a forward P/E ratio of -21.32, indicating a lack of profitability.